Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma

Research output: Contribution to journalArticlepeer-review

Abstract

Two reports describe the problem of secondary malignancies in patients with LGL. Bennett and colleagues find that I 131 tositumomab (Bexxar) following alkylating agent therapy does not increase the risk of tMDS or tAML, while McLaughlin and colleagues find that this risk is increased following fludarabine-based therapy.

Original languageEnglish (US)
Pages (from-to)4543-4544
Number of pages2
JournalBlood
Volume105
Issue number12
DOIs
StatePublished - Jun 15 2005

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma'. Together they form a unique fingerprint.

Cite this